Heart failure - Pipeline Insight, 2021
This report can be delivered to the clients within 2-3 Business Days
DelveInsight’s, “Heart failure - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Heart failure pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Heart failure: Overview
Heart Failure, also known as congestive heart failure refers to the condition when heart is not able to pump adequate blood to the body. In the absence of sufficient blood flow, all the major body functions are disrupted. Certain conditions, such as narrowed arteries in the heart (coronary artery disease) or high blood pressure, gradually leave the heart too weak or stiff to fill and pump efficiently. Heart failure can be diagnosed based on the medical and family history, a physical exam, and test results. Treating heart failure depends on the severity of the condition. Diagnostic tests include: electrocardiogram, chest X-Ray, echocardiography etc. Treatments usually include heart-healthy lifestyle changes, medicines, and ongoing care.
'Heart failure - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Heart failure pipeline landscape is provided which includes the disease overview and Heart failure treatment guidelines. The assessment part of the report embraces, in depth Heart failure commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Heart failure collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Heart failure report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Heart failure Emerging Drugs
Further product details are provided in the report……..
Heart failure: Therapeutic Assessment
This segment of the report provides insights about the different Heart failure drugs segregated based on following parameters that define the scope of the report, such as:
Heart failure: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Heart failure therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Heart failure drugs.
Heart failure Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Heart failure - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Heart failure pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Heart failure: Overview
Heart Failure, also known as congestive heart failure refers to the condition when heart is not able to pump adequate blood to the body. In the absence of sufficient blood flow, all the major body functions are disrupted. Certain conditions, such as narrowed arteries in the heart (coronary artery disease) or high blood pressure, gradually leave the heart too weak or stiff to fill and pump efficiently. Heart failure can be diagnosed based on the medical and family history, a physical exam, and test results. Treating heart failure depends on the severity of the condition. Diagnostic tests include: electrocardiogram, chest X-Ray, echocardiography etc. Treatments usually include heart-healthy lifestyle changes, medicines, and ongoing care.
'Heart failure - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Heart failure pipeline landscape is provided which includes the disease overview and Heart failure treatment guidelines. The assessment part of the report embraces, in depth Heart failure commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Heart failure collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Heart failure R&D. The therapies under development are focused on novel approaches to treat/improve Heart failure.
This segment of the Heart failure report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Heart failure Emerging Drugs
- Finerenone: Bayer HealthCare Pharmaceuticals
- IONIS-AGT-LRx: Ionis Pharmaceuticals
Further product details are provided in the report……..
Heart failure: Therapeutic Assessment
This segment of the report provides insights about the different Heart failure drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Heart failure
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Heart failure: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Heart failure therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Heart failure drugs.
Heart failure Report Insights
- Heart failure Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Heart failure drugs?
- How many Heart failure drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Heart failure?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Heart failure therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Heart failure and their status?
- What are the key designations that have been granted to the emerging drugs?
- Bayer HealthCare Pharmaceuticals
- Ionis Pharmaceuticals
- Heartseed Inc.
- AstraZeneca
- Amgen
- Sardocor Corp.
- Intra-Cellular Therapies
- Bristol Myers Squibb
- Eli Lilly and Company
- Palatin Technologies
- Cardiora
- Zensun Sci. & Tech. Co., Ltd.
- Biopeutics Co., Ltd
- Innolife Co., Ltd.
- SQ Innovation
- scPharmaceuticals
- Mesoblast, Inc
- PhaseBio Pharmaceuticals
- Salubris Biotherapeutics Inc
- Actelion Pharmaceuticals
- Torrent Pharmaceuticals Limited
- Novo Nordisk A/S
- Shanghai Hongyitang Biopharmaceutical Technology Co. Ltd.
- Merck Sharp & Dohme Corp.
- Cardior Pharmaceuticals GmbH
- Pfizer
- MyoKardia, Inc.
- TransThera Biosciences Co., Ltd
- Acceleron Pharma Inc.
- Asklepios Biopharmaceutical, Inc.
- Bial
- Finerenone
- IONIS-AGT-LRx
- HS 001
- AZD 4831
- Omecamtiv Mecarbil
- SRD-001
- ITI-214
- BMS-986259
- LY3461767
- PL-3994
- CRD-102
- rhNRG-1
- INL1
- SQIN-01
- Furoscix Infusor
- Allogeneic Mesenchymal Precursor Cells (MPC)
- PB1046
- JK07
- Macitentan
- TRC041266
- Semaglutide
- TSG-01
- Ertugliflozin
- CDR132L
- Sildenafil Citrate
- Mavacamten
- TT-00920
- Sotatercept
- NAN-101
- BIA 5-1058
Introduction
Executive Summary
Heart failure: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Heart failure – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Heart failure companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Heart failure Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Finerenone: Bayer HealthCare Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
IONIS-AGT-LRx: Ionis Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
NAN-101: Asklepios BioPharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Heart failure Key Companies
Heart failure Key Products
Heart failure- Unmet Needs
Heart failure- Market Drivers and Barriers
Heart failure- Future Perspectives and Conclusion
Heart failure Analyst Views
Heart failure Key Companies
Appendix
Executive Summary
Heart failure: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Heart failure – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Heart failure companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Heart failure Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Finerenone: Bayer HealthCare Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
IONIS-AGT-LRx: Ionis Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
NAN-101: Asklepios BioPharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Heart failure Key Companies
Heart failure Key Products
Heart failure- Unmet Needs
Heart failure- Market Drivers and Barriers
Heart failure- Future Perspectives and Conclusion
Heart failure Analyst Views
Heart failure Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Heart failure
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Heart failure
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Heart failure
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Heart failure
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
